Clinical Trial Update: A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib in locally advanced or metastatic non-small cell lung cancer with EGFR mutations has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-10-26